🇺🇸 FDA
Patent

US 8052970

Lysosomal phospholipase A2 (LPLA2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis

granted A61KA61K38/45A61K38/465

Quick answer

US patent 8052970 (Lysosomal phospholipase A2 (LPLA2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis) held by THE REGENTS OF THE UNIVERSITY OF MICHIGAN expires Mon Nov 03 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Grant date
Tue Nov 08 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 03 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61K, A61K38/45, A61K38/465, A61P, A61P11/00